ArticleiGIE : innovation, investigation and insights2024
Incidence rates of Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.
Article in iGIE : innovation, investigation and insights, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Barrett's oesophagus surveillance in a centralised system: implications for progression risk and management.Journal of thoracic disease · 2026Article
- Identification ofDiagnostics (Basel, Switzerland) · 2024Article
- Exploring vision transformers for classifying early Barrett's dysplasia in endoscopic images: A pilot study on white-light and narrow-band imaging.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Barrett's esophagus (BE) surveillance is commonly performed to detect early dysplasia and esophageal adenocarcinoma (EAC). However, high-quality incidence rates for the development of dysplasia and EAC in patients with BE are limited. The aim of this study was to perform a systematic review and meta-analysis to provide updated incidence rates for the development of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and EAC in a population of patients with BE undergoing endoscopic surveillance. Methods: We performed a systematic search of Embase and MEDLINE from inception to September 2022. The goal was to identify studies reporting the incidence rates of LGD, EAC, or HGD/EAC as an outcome in patients with nondysplastic BE (NDBE), LGD, or HGD. Respective pooled incidence rates were estimated by using a meta-analysis. Results: Twenty-five studies were included in this meta-analysis comprising 2587 patients with a combined follow-up of 218,351 person-years. For patients with NDBE, pooled incidence rates for progression to LGD, HGD, EAC, and HGD/EAC were 4.29, .52, .21, and .57 per 100 person-years, respectively. For patients with LGD, pooled incidence rates were 3.18 (HGD), 1.16 (EAC), and 5.05 (HGD/EAC) per 100 person-years. For those with HGD, the pooled incidence rate for EAC was 14.16 per 100 person-years. Conclusions: Progression to EAC and HGD/EAC remained low for patients with NDBE. Patients with confirmed (by ≥2 pathologists) LGD may be more likely to develop EAC, prompting a need to assess current BE surveillance strategies in this group.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.